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INTRODUCTION
▪ Tissue plasminogen activator (tPA) was first approved by the
Food and Drug Administration (FDA) in 1996 for the treatment of
acute ischemic stroke.2

N=50

▪ Primary endpoint is to compare stroke patients who received tPA
with a DTN time <60 minutes with and without a pharmacist
present.
▪ Secondary endpoint is the accuracy of the patient’s weight used
to calculate the tPA dose with and without a pharmacist present.

Male (%)

Female (%)

67

44

56

81 (52-118)

66

48

52

81 (56-141)

0.87

0.77

▪ Data collection included ED arrival time, tPA administration time,
patient’s weight used for tPA dosing, and patient’s weight postadmission (within 72 hours).

This review shows the potential benefits of having a pharmacist
as a member of the stroke team.

•

The percent of patients with a DTN <60 minutes was higher with
a pharmacist absent and was likely due to confounding variables
and a small sample size. Regardless, both groups were above
the national average and the DTN time was improved by an
average of 9 minutes when a pharmacist was present.

• tPA was more accurately dosed when the pharmacist was
present. This is likely due to the pharmacist weighing the patient
using a scale or ED bed, instead of using the patient’s stated
weight to dose tPA.
• In accordance with the American Stroke Association/American
Heart Association “Target: Stroke” initiative, the pharmacist may
play a significant role in preparing the tPA ahead of time and
having it available for rapid access.3
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• The future goal at GMC is to have 75% of patients receive tPA
within 60 minutes, of which half of those patients should have a
DTN time < 45 minutes.

Minutes

Percent of patients

Gwinnett Core
National
Medical Measure Average
Center

Gwinnett Core National
Medical Measure Average
Center

REFERENCES

Average DTN
Time

Secondary Endpoint

Percent of patients
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METHODS
▪ Conducted a retrospective chart review of patients who were
administered tPA for the treatment of ischemic stroke from
August 2015 to August 2016.
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▪ Door-to-needle (DTN) time is defined as the time between the
arrival to the emergency department (ED) and the administration
of the tPA bolus dose; the national goal DTN time is less than 60
minutes. Studies have shown a statistically significant decrease in
mortality for every 15-minute reduction in time to tPA
administration.4
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▪ Gwinnett Medical Center (GMC) is a 500-bed community hospital
and an advanced primary stroke center. tPA is dosed using a
chart with pre-determined total dose, bolus dose and infusion
doses based on the patient’s weight, which is rounded to 2-3 kg
intervals.

▪ At GMC, an ED pharmacist is only present during the hours of
1:30 pm to midnight seven days a week and has been a part of
the ED stroke team since August 2015.

•

Patient Demographics

▪ tPA is given intravenously (IV) and dosed based on the patient’s
weight. Studies have shown that tPA is dosed incorrectly in 29%
of cases due to weight discrepancies.1 Inaccurately dosing tPA is
associated with negative outcomes, including bleeding.1

▪ To meet core measures, 50% of patients must receive tPA
within 60 minutes. However, nationwide only 30% of patients
receive tPA within this window.3
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